Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs

Compass Therapeutics

06/08/2026 12:46

Overview
US oncology biopharma's Q2 net loss widened yr/yr on higher R&D and G&A expenses
Company ended Q2 with $180 mln in cash and marketable securities, expects runway into 2028

Result Drivers
TOVECIMIG DEVELOPMENT - Co said higher R&D expenses were primarily due to increased spending on tovecimig
PRE-COMMERCIALIZATION SPENDING - Co attributed higher G&A expenses to increased pre-commercialization costs

Company press release: ID:nGNX38yTtp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$25.15 mln
 
Q2 Loss Per Basic Share
 
$0.13
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Compass Therapeutics Inc. is $6.50, about 243.9% above its August 5 closing price of $1.89

Reuters Recommended Reads
Aug 5 - Context Therapeutics Q2 net loss widens on higher R&D costs
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Aug 4 - Tyra Biosciences Q2 net loss widens on higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)